Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
SSII
SS Innovations International, Inc.
Core product: robotic surgical system and endo-surgical instruments (SSi Mantra and related tools) sold as surgical equipment.
|
$1.15B |
$5.88
+6.43%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's pipeline centers on neuropsychiatric drug development, placing it in the Neuropsychiatric Drug Development investable theme.
|
$1.15B |
$15.02
+2072.72%
|
|
THRM
Gentherm Incorporated
Medical devices & biometrics including patient temperature management devices.
|
$1.13B |
$36.92
-2.97%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$1.11B |
$24.39
+1.46%
|
|
TDOC
Teladoc Health, Inc.
Integrated Care delivers virtual medical, mental health, and chronic condition management services.
|
$1.11B |
$6.28
-3.91%
|
|
PVLA
Palvella Therapeutics, Inc.
Palvella Therapeutics concentrates on rare genetic skin diseases and markets a proprietary topical rapamycin platform (QTORIN), indicating a core focus on rare disease biotech development.
|
$1.10B |
$99.88
-3.94%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
SANA
Sana Biotechnology, Inc.
Sana's lead platform is HIP-modified cell therapy (ex vivo) for allogeneic cell transplantation.
|
$1.09B |
$4.58
-1.82%
|
|
ACHC
Acadia Healthcare Company, Inc.
ACHC is a pure-play behavioral health provider delivering inpatient and outpatient mental health and substance use treatment services.
|
$1.08B |
$11.67
-2.02%
|
|
MLTX
MoonLake Immunotherapeutics
MoonLake focuses on immunology therapeutics with Sonelokimab (SLK) for inflammatory skin and joint diseases.
|
$1.08B |
$16.76
+2.51%
|
|
CDNA
CareDx, Inc
Directly provides Laboratory Testing & Advisory Services through its testing portfolio and diagnostic operations.
|
$1.07B |
$20.00
-2.77%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$1.05B |
$17.00
+0.24%
|
|
CVAC
CureVac N.V.
CureVac's core focus is oncology immunotherapies and cancer vaccines built on its mRNA platform (Biotech - Oncology).
|
$1.05B |
$4.66
|
|
BFLY
Butterfly Network, Inc.
Core ultrasound imaging hardware and point-of-care devices (POCUS) produced by Butterfly.
|
$1.05B |
$4.14
-9.01%
|
|
INBX
Inhibrx Biosciences, Inc.
Clinical-stage oncology biotech with DR5 and OX40 antibody programs.
|
$1.05B |
$72.46
+0.92%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$1.04B |
$10.13
-3.52%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$1.04B |
$15.08
-4.80%
|
|
STAA
STAAR Surgical Company
STAAR directly manufactures ophthalmic medical devices, primarily implantable lenses (EVO ICL) used for vision correction.
|
$1.04B |
$20.98
+0.05%
|
|
ALNT
Allient Inc.
Medical Device Components align with Allient’s product capabilities used in medical device applications.
|
$1.04B |
$61.37
-0.72%
|
|
ERAS
Erasca, Inc.
Erasa is a clinical-stage biotechnology company developing targeted cancer therapies, i.e., Biotech - Oncology.
|
$1.02B |
$3.58
+6.07%
|
|
OPK
OPKO Health, Inc.
OPKO's BioReference segment provides laboratory testing and advisory services.
|
$1.02B |
$1.29
+0.78%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$1.01B |
$20.02
-0.47%
|
|
PNTG
The Pennant Group, Inc.
Pennant's direct service offerings include Home Health and Hospice care across the post-acute continuum.
|
$1.01B |
$29.16
-2.46%
|
|
SVRA
Savara Inc.
Molgramostim is a recombinant GM-CSF protein delivered as an inhalation therapy; directly a recombinant protein/enzymes product.
|
$1.00B |
$5.58
-3.79%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$1.00B |
$3.93
+6.50%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$997.47M |
$14.09
-5.97%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$995.49M |
$21.00
-0.83%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$990.48M |
$13.88
+0.14%
|
|
VERV
Verve Therapeutics, Inc.
Verve Therapeutics' core offering is in vivo gene therapy using base editing delivered to liver cells, aligning with Biotech - Gene Therapy.
|
$988.30M |
$11.13
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Lead asset RAP-219 is a small molecule AMPAR NAM targeting neuronal ion channels, i.e., ion channel modulators.
|
$978.51M |
$26.81
-0.19%
|
Showing page 14 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
